Domenech J, Roingeard F, Hérault O, Truglio D, Desbois I, Colombat P, Binet C
Laboratory of Hematology, Bretonneau University Hospital, Tours, France.
Leuk Lymphoma. 1998 May;29(5-6):533-46. doi: 10.3109/10428199809050913.
Marrow stromal cells were evaluated several months after autologous BMT for their capacity to support both normal hemopoiesis and secrete the main growth factors involved in its control, G-CSF, GM-CSF, IL-3 and SCF. Stromal layers (SL) were obtained by long-term marrow cultures (LTMC) established from 15 patients (9 with hematologic malignancies and 6 with solid tumors) 3 months after autologous BMT and were compared to pre-graft patients. After irradiation, both post-graft and pre-graft SL were recharged with the same inoculum of normal marrow cells. As compared to pre-graft values, CFU-GM production on post-graft SL was significantly increased during the first 2 weeks of culture whereas it was decreased from week 3 to week 8. These findings were only observed in patients with hematologic malignancies and not in patients with solid tumors. Growth factor secretion was evaluated by ELISA in the supernatants of unstimulated and IL-1-stimulated SL from 10 post-graft patients, 13 pre-graft patients and 5 normal controls. In any group of patients, IL-3 was undetectable either spontaneously or after IL-1-stimulation. As compared to controls, secretion by IL-1-stimulated SL was not different for GM-CSF in pre- and post-graft patients but tended to be decreased for G-CSF in post-graft patients. SCF secretion, which was not induced by IL-1, appeared dramatically decreased in both pre- and post-graft patients. The capacity of post-graft SL to support CFU-GM growth in LTMC was correlated at week 1 with G-CSF secretion and from week 3 to week 8 with SCF secretion. These results suggest that microenvironment remains qualitatively damaged several months after BMT involving a decreased capacity both to support early hemopoiesis and to secrete SCF, particularly in patients grafted for hemopoietic malignancies.
在自体骨髓移植(BMT)数月后,对骨髓基质细胞支持正常造血以及分泌参与造血调控的主要生长因子(粒细胞集落刺激因子(G-CSF)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白细胞介素-3(IL-3)和干细胞因子(SCF))的能力进行了评估。从15例患者(9例血液系统恶性肿瘤患者和6例实体瘤患者)自体BMT后3个月建立的长期骨髓培养(LTMC)中获取基质层(SL),并与移植前患者的基质层进行比较。照射后,移植后和移植前的SL均接种相同接种量的正常骨髓细胞。与移植前的值相比,移植后SL上的CFU-GM产量在培养的前2周显著增加,而从第3周到第8周则下降。这些发现仅在血液系统恶性肿瘤患者中观察到,而在实体瘤患者中未观察到。通过酶联免疫吸附测定(ELISA)对10例移植后患者、13例移植前患者和5例正常对照的未刺激和IL-1刺激的SL上清液中的生长因子分泌进行了评估。在任何一组患者中,无论是自发还是IL-1刺激后,均未检测到IL-3。与对照组相比,移植前和移植后患者中IL-1刺激的SL分泌GM-CSF没有差异,但移植后患者中G-CSF的分泌倾向于减少。未被IL-1诱导的SCF分泌在移植前和移植后患者中均显著降低。移植后SL在LTMC中支持CFU-GM生长的能力在第1周与G-CSF分泌相关,从第3周到第8周与SCF分泌相关。这些结果表明,在BMT数月后,微环境在质量上仍然受损,支持早期造血和分泌SCF的能力下降,特别是在接受造血恶性肿瘤移植的患者中。